Alterity Therapeutics Limited, (formerly Prana Biotechnology Limited) is meeting this week with sophisticated investors in both Singapore and Hong Kong in the first leg of a global investor roadshow.

We wish to announce the Company name change has been processed by the Australian Securities and Investment Commission and the Company has changed its name from “Prana Biotechnology Limited” to “Alterity Therapeutics Limited”.

Alterity Therapeutics Limited (formerly Prana Biotechnology Limited) (ASX:PBT) (“Alterity” or “the Company”) is pleased to announce completion of the strategic investment by Life Biosciences LLC (Life) of an initial US$7.5m (A$10.526m at an exchange rate of A$1.00 to US$0.7125) in the Company (Subscription).

The Company wishes to advise that all resolutions contained in the Notice of Meeting were carried on a show of hands.

Prana Biotechnology today advises that a conference call facility will be available at the Extraordinary General Meeting (EGM) scheduled for Friday, April 5, 2019, at 11:00 AM AEDT.

Prana has today announced that is has received a A$3.3 million cash refund under the Australian Government’s R&D Tax Incentive Scheme.

Notice of General Meeting 2019

Prana receives first orphan drug designation from the FDA for the treatment of Multiple System Atrophy

Prana Biotechnology BSC Presntation 20180107 FINAL

Prana's Chief Medical Officer Dr David Stamler, MD will present at the Biotech Showcase in San Francisco on Monday 7th January, US Pacific Standard Time.